Palsonify Tablet, Film Coated
Product Images NDC 84015-920

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Palsonify (NDC 84015-920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Crinetics Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Pal0h 0002 01)

Chemical structure of paltusotine, showing its molecular framework with elements including nitrogen, fluorine, hydroxyl, and cyanide groups connected within aromatic and heterocyclic rings.*

FDA Label Image

Principal Display Panel (Pal0h 0002 02)

Label for Palsonify (paltusotine) oral tablets, 20 mg strength, manufactured by Crinetics Pharmaceuticals, Inc. The label states storage instructions (20°C to 25°C) and contains regulatory information including NDC, GTIN, barcode, and logo. Package size indicated is 60 tablets.*

FDA Label Image

Principal Display Panel (Pal0h 0002 03)

Palsonify (paltusotine) 30 mg film-coated oral tablets packaging label. The label indicates 60 tablets per container, manufactured for Crinetics Pharmaceuticals, Inc. Storage instructions specify 20°C to 25°C with permitted excursions. The label includes dosage instructions to refer to full prescribing information and features a barcode and identification codes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.